Breast cancer market will capture major-market sales of almost $20 billion in 2024

The breast cancer market will have grown to almost $20 billion across the major markets (USA, France, Germany, Italy, Spain, UK and Japan), corresponding to an impressive annual growth rate of 5%.

According to a new report from Decision Resources Group, this growth will be fuelled by continued uptake of Roche (ROG: SIX)/Genentech/Chugai's Perjeta (pertuzumab) and Kadcyla (trastuzumab-DM1) for HER2-positive disease, Pfizer's (NYSE: PFE) Ibrance (palbociclib) for hormone receptor (HR)-positive, HER2-negative disease, and the launch of several novel therapies, notably Roche/Genentech/Chugai's PD-L1 inhibitor, atezolizumab for triple-negative disease.

Sales of recently launched and emerging therapies will more than offset the continued generic erosion of key current therapies, including the biosimilar erosion of trastuzumab (Roche/Genentech/Chugai's Herceptin).